# SGN35-027 (NCT03646123)

> Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03646123
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Seagen Inc.
- Conditions: Hodgkin Lymphoma
- Interventions: brentuximab vedotin; doxorubicin; vinblastine; dacarbazine; G-CSF; nivolumab
- Enrollment: 255
- Primary outcome: Febrile Neutropenia (FN) Rate (Part A)
- Primary outcome: Complete Response (CR) Rate at EOT (Parts B and C)

## Indexed commentary on SGN35-027 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=sgn35-027-nct03646123